Home - Products - Angiogenesis - PDE - 5,7-Diacetoxy-8-methoxyflavone

5,7-Diacetoxy-8-methoxyflavone

CAS No. 23246-80-2

5,7-Diacetoxy-8-methoxyflavone ( ZINC77031696 )

Catalog No. M29268 CAS No. 23246-80-2

5,7-Diacetoxy-8-methoxyflavone is derived from the roots of Scutellaria baicalensis and inhibits cAMP phosphodiesterase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 408 Get Quote
10MG 601 Get Quote
25MG 945 Get Quote
50MG 1278 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    5,7-Diacetoxy-8-methoxyflavone
  • Note
    Research use only, not for human use.
  • Brief Description
    5,7-Diacetoxy-8-methoxyflavone is derived from the roots of Scutellaria baicalensis and inhibits cAMP phosphodiesterase.
  • Description
    5,7-Diacetoxy-8-methoxyflavone is derived from the roots of Scutellaria baicalensis and inhibits cAMP phosphodiesterase.
  • Synonyms
    ZINC77031696
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    23246-80-2
  • Formula Weight
    368.3
  • Molecular Formula
    C20H16O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC=1C=C(OC(=O)C)C=2C(=O)C=C(OC2C1OC)C=3C=CC=CC3)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • BRL 50481

    BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15 12.1 62 and 490 μM for PDE7A PDE7B PDE4 and PDE3 respectively.

  • BW-A78U

    BW-A 78U is a PDE4 inhibitor (IC50: 3 μM). It is not inhibition on the lipopolysaccharide (LPS)-induced TNF-α release.

  • Mirodenafil

    Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.